TP53 and adenocarcinoma: A thorough review of the previous literature revealed that 4.5% (3/67) of vaginal/cervical MAs and 0.9% (1/112) of uterine/ovarian mesonephric-like adenocarcinomas harbor <i>TP53</i> mutations, indicating that this is very uncommon in malignant mesonephric lesions.